S78 Abstracts Agarkov, A.A., Wilffert, B., Loonen, A.J.M., 2017. Identifi- cation of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World J. Biol. Psychiatry 18 (3), 239–246. [4] Ivanova, S.A., Osmanova, D.Z., Boiko, A.S., Pozhidaev, I.V., Freidin, M.B., Fedorenko, O.Y., Semke, A.V., Bokhan, N.A., Ko- rnetova, E.G., Rakhmazova, L.D., Wilffert, B., Loonen, A.J.M., 2017. Prolactin gene polymorphism (-1149 G/T) is associ- ated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophr Res 182, 110–114. doi: 10.1016/j.schres.2016.10.029 P.086 25-OH vitamin D level is associated with the episodic memory in young male patients with schizophrenia spectrum disorders P. Švancer 1,2,∗ , M. Kopeˇcek 1,2 , V. Andrashko 1,2 , P. Knytl 1,2 , A. Dorazilová 1,3 , V. Voráˇcková 1,2 , M. Rodriguez 1 , P. Mohr 1,2 , F. Španiel 1,2 1 National Institute Of Mental Health, Inpatient Ward, Kle- cany, Czech Republic 2 Charles University, Third Faculty of Medicine - Depart- ment of Psychiatry, Prague, Czech Republic 3 Masaryk University, Department of Psychology, Brno, Czech Republic Background: Vitamin D deficiency (25(OH)D) is a likely risk factor for neuropsychiatric disorders. Human studies that examined the relationship between vitamin D status and cognitive function have provided inconclusive results. In a recent study the concentration of 25(OH)D negatively cor- related with the size of the cerebral ventricles [1] and in another study the concentration of 25(OH)D positively cor- related in patients with schizophrenia with the volume of the right hippocampus [2]. In our previous pilot study, we found a positive correlation between episodic memory per- formance and 25(OH)D in 16 men. Objective: The aim of our study was to verify the hypothesis that the serum 25-OH concentration of vitamin D is associ- ated with performance in the episodic memory of men. In our curent study we used a larger sample than in the pilot study. Methods: The study included 29 men with schizophre- nia spectrum disorder at the age of 21 ± 2.5 years with an average concentration of 25(OH)D of 42 ± 21 nmol/L. Serum 25(OH)D concentration was determined by electrochemiluminescence on Elecsys immunoassays from Roche. In order to eliminate the circannual influence of 25(OH)D in serum, the concentration of 25(OH)D was cor- rected for the month of collection. All patients were exam- ined by a memory learning test (AVLT). The relationship be- tween concentration of 25(OH)D and AVLT was analyzed by one-way analysis of variance (ANOVA). We evaluated learn- ing ability, number of recalled words after interference and 30 minutes after interference. Subjects were divided into three groups based on levels of 25(OH): group 1 (concen- tration below 25 nmol/L, severe deficiency), group 2 (25- 50 nmol/L, slight deficiency) and group 3 (over 50 nmol/L, without deficiency). The significance level was determined to be less than 0.05. Results: Eight individuals had a concentration of 25(OH)D below 25 nmol/L, fourteen in the range of 25-50 nmol/L and seven above 50 nmol/L. One-way ANOVA confirmed the as- sociation of 25(OH)D serum concentration with the learning performance (p = 0.047), delayed recall after interference (p = 0.006) and recall after 30 minutes (p = 0.015). In post hoc testing, there was a significant difference between se- vere deficiency group and without deficiency group in all endpoints. Significant differences between severe and mild deficiency groups were detected in the recall of words after interference and also 30 minutes after interference. No sig- nificant difference was found between the slight deficiency group and without deficiency group in any parameter. Conclusion: Subjects with severe 25(OH)D deficiency per- formed worse compared to subjects with slight or no defi- ciency. Our results also reflect the widely present deficiency of 25(OH)D in schizophrenia spectrum patients. The results confirm our hypothesis, but do not exclude the possibility of reverse causality. An intervention study should be con- ducted to confirm the causality between 25(OH)D and per- formance in episodic memory. References [1] Annweiler, C., Annweiler, T., Montero-Odasso, M., Bartha, R., Beauchet, O., 2014. Vitamin D and brain volumetric changes: Systematic review and meta-analysis. Maturitas 78 (1), 30–39. [2] Shivakumar, V., Kalmady, S.V., Amaresha, A.C., Jose, D., Narayanaswamy, J.C., Agarwal, S.M., et al., 2015. Serum vita- min D and hippocampal gray matter volume in schizophrenia. Psychiatry Res 233 (2), 175–179. doi: 10.1016/j.euroneuro.2019.09.144 P.089 Pimavanserin behaves as serotonin 5-HT2A re- ceptor inverse agonist selective for gαi/o but not gαq/11 proteins in human prefrontal cortex I. Muneta-Arrate 1,∗ , R. Diez-Alarcia 1,2 , I. Horrillo 1,2 , J.J. Meana 1,2 1 CIBERSAM and University of the Basque Country UPV/EHU, Department of Pharmacology, Leioa- Bizkaia, Spain 2 Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain Background: Several in vitro studies in the literature show a change in the density of cortical 5-HT2A receptors (5- HT2AR) in the post-mortem brain of schizophrenic subjects. These changes seem to be related with a different con- formational state of receptor itself or by interaction with different effector proteins. In this context, 5-HT2AR has been demonstrated to couple to both canonical Gαq/11 pathway and to Gαi1 proteins depending on the binding drug, a mechanism called biased agonism. Previous data described a supersensitivity of the Gαi1-protein-coupled conformation and signalling of 5-HT2AR in brain with sub- jects with schizophrenia, while coupling to Gαq/11 remain unchanged.